Actively Recruiting
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis
Led by Far Eastern Memorial Hospital · Updated on 2024-07-26
2600
Participants Needed
1
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific "red-flag" signs of Fabry disease in Taiwan.
CONDITIONS
Official Title
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Presence of left ventricular hypertrophy (LVH) on echocardiography or cardiac MRI
- Maximal interventricular septal or posterior wall thickness of 13 mm or more
- Apical wall thickness of 15 mm or more or an apical to basal left ventricular wall thickness ratio of 1.3 or higher at end-diastole
- Maximal left ventricular wall thickness of 15 mm or more in any other part
- Male or female adults aged 20 years or older
- Willingness to comply with the study and sign informed consent
You will not qualify if you...
- Patients who refuse or are unable to give informed consent
- Patients unlikely to comply with the study protocol or unable to understand the nature and possible consequences of the program
- Presence of coarctation of the aorta, severe aortic stenosis, or severe left ventricular pressure overload
- Diagnosis of athletic heart
- Diagnosis of non-compaction cardiomyopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Far Eastern Memorial Hospital
New Taipei City, Taiwan, 220
Actively Recruiting
Research Team
Y
Yen-Wen Wu, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here